Literature DB >> 28321586

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

K Matter-Walstra1,2, M Schwenkglenks3, K J Dedes4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28321586     DOI： 10.1007/s10549-017-4209-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  5 in total

Review 1.  Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.

Authors:  Esther S Kim; Lesley J Scott
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

Review 2.  Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

Authors:  Jinani Jayasekera; Jeanne S Mandelblatt
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 3.  Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.

Authors:  Linhui Zhu; Mengmeng Wang; Xin Luo; Huan Li; Han Shan; Qiong Du; Qing Zhai
Journal:  Ann Transl Med       Date:  2022-02

4.  Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.

Authors:  Katya Galactionova; Sibylle Loibl; Paola Salari; Frederik Marmé; Miguel Martin; Michael Untch; Hervé R Bonnefoi; Sung-Bae Kim; Harry D Bear; Nicole McCarthy; Karen A Gelmon; José A García-Sáenz; Catherine M Kelly; Toralf Reimer; Masakazu Toi; Hope S Rugo; Michael Gnant; Andreas Makris; Nicole Burchardi; Matthias Schwenkglenks
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

5.  Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.

Authors:  Yannan Zhao; Yi Li; Chengcheng Gong; Yizhao Xie; Jian Zhang; Leiping Wang; Jun Cao; Zhonghua Tao; Biyun Wang; Xichun Hu
Journal:  Cancer Med       Date:  2020-10-06       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.